AstraZeneca's PDL-1 data hint at immunotherapy breadth
This article was originally published in Scrip
Executive Summary
AstraZeneca claims to have one of the broadest immunotherapy portfolios in the pharmaceutical industry, led by its programmed cell death ligand-1 (PDL-1) inhibitor MEDI4736, and recent data from the company show a glimpse of the immuno-oncology platform's breadth.